natgillin/translations-raw huggingface dataset:
In addition, the film coating contains: poly(vinyl alcohol), macrogol 3350, talc (E553b), titanium dioxide (E171), iron oxide red (E172), and iron oxide black (E172). 
Osim toga, ovojnica tablete sadrži : poli(vinilni alkohol), makrogol 3350, talk (E553b), titanijev dioksid (E171), crveni željezov oksid (E172) i crni željezov oksid (E172).
Study of sitagliptin in combination with metformin and insulin A 24-week placebo-controlled study was designed to evaluate the efficacy and safety of sitagliptin (100 mg once daily) added to insulin (at a stable dose for at least 10 weeks) with or without metformin (at least 1,500 mg). 
U 24-tjednom placebom kontroliranom ispitivanju cilj je bio ocijeniti djelotvornost i sigurnost sitagliptina (100 mg jedanput na dan) dodanog inzulinu (u stabilnoj dozi tijekom najmanje 10 tjedana) s ili bez metformina (najmanje 1500 mg).
Ristfor 50 mg/850 mg film-coated tablets 
Ristfor 50 mg/850 mg filmom obložene tablete
Body weight did not increase from baseline with sitagliptin therapy. 
Terapija sitagliptinom nije dovela do porasta tjelesne težine u odnosu na početnu.
Study of sitagliptin in combination with metformin and a sulphonylurea A 24-week placebo-controlled study was designed to evaluate the efficacy and safety of sitagliptin (100 mg once daily) added to glimepiride (alone or in combination with metformin). 
Ispitivanje sitagliptina u kombinaciji s metforminom i sulfonilurejom U 24-tjednom placebom kontroliranom ispitivanju cilj je bio ocijeniti djelotvornost i sigurnost sitagliptina (100 mg jedanput na dan) kao dodatka liječenju glimepiridom (samom ili u kombinaciji s metforminom).
Common flatulence 
Bulozni pemfigoid
These included hypoglycaemia (frequency very common with sulphonylurea or insulin), constipation (common with sulphonylurea), peripheral oedema (common with pioglitazone), and headache and dry mouth (uncommon with insulin). 
Neke nuspojave su primijećene češće u ispitivanjima kombinirane primjene sitagliptina i metformina s drugim lijekovima za liječenje dijabetesa nego u ispitivanjima sitagliptina i metformina samih.To je uključivalo hipoglikemiju (učestalost vrlo česta sa sulfonilurejom ili inzulinom), konstipaciju (česta sa sulfonilurejom), periferni edem (česta s pioglitazonom) te glavobolju i suha usta (manje česta s inzulinom).
Ristfor 50 mg/1,000 mg film-coated tablets 
Ristfor 50 mg/1000 mg filmom obložene tablete
Sitagliptin 50 mg + metformin 1,000 mg (N=178) 
početna terapija (dvaput na dan) sitagliptin 50 mg + metformin 500 mg (n=183) početna terapija (dvaput na dan) sitagliptin 50 mg + metformin 1000 mg (n=178)
Adverse reactions were identified through post-marketing surveillance. 
Nuspojave su utvrđene praćenjem nakon stavljanja lijeka u promet.
In addition, the film coating contains the following inactive ingredients: poly(vinyl alcohol), macrogol 3350, talc (E553b), titanium dioxide (E171), iron oxide red (E172), and iron oxide black (E172). 
Osim toga, ovojnica tablete sadrži: poli(vinilni alkohol), makrogol 3350, talk (E553b), titanijev dioksid (E171), crveni željezov oksid (E172) i crni željezov oksid (E172).
See section 2, Do not take Ristfor. 
Nemojte uzimati Ristfor.
EU/1/10/620/009 14 film-coated tablets EU/1/10/620/010 28 film-coated tablets EU/1/10/620/011 56 film-coated tablets EU/1/10/620/021 60 film-coated tablets EU/1/10/620/012 112 film-coated tablets EU/1/10/620/013 168 film-coated tablets EU/1/10/620/022 180 film-coated tablets EU/1/10/620/014 196 film-coated tablets EU/1/10/620/015 50 x 1 film-coated tablets EU/1/10/620/016 196 (2 x 98) film-coated tablets EU/1/10/620/018 168 (2 x 84) film-coated tablets 
EU/1/10/620/009 14 filmom obloženih tableta EU/1/10/620/010 28 filmom obloženih tableta EU/1/10/620/011 56 filmom obloženih tableta EU/1/10/620/021 60 filmom obloženih tableta EU/1/10/620/012 112 filmom obloženih tableta EU/1/10/620/013 168 filmom obloženih tableta EU/1/10/620/022 180 filmom obloženih tableta EU/1/10/620/014 196 filmom obloženih tableta EU/1/10/620/015 50 x 1 filmom obložena tableta EU/1/10/620/016 196 (2 x 98) filmom obloženih tableta EU/1/10/620/018 168 (2 x 84) filmom obloženih tableta
EU/1/10/620/001 14 film-coated tablets EU/1/10/620/002 28 film-coated tablets EU/1/10/620/003 56 film-coated tablets EU/1/10/620/019 60 film-coated tablets EU/1/10/620/004 112 film-coated tablets EU/1/10/620/005 168 film-coated tablets EU/1/10/620/020 180 film-coated tablets EU/1/10/620/006 196 film-coated tablets EU/1/10/620/007 50 x 1 film-coated tablets EU/1/10/620/008 196 (2 x 98) film-coated tablets EU/1/10/620/017 168 (2 x 84) film-coated tablets 
EU/1/10/620/001 14 filmom obloženih tableta EU/1/10/620/002 28 filmom obloženih tableta EU/1/10/620/003 56 filmom obloženih tableta EU/1/10/620/019 60 filmom obloženih tableta EU/1/10/620/004 112 filmom obloženih tableta EU/1/10/620/005 168 filmom obloženih tableta EU/1/10/620/020 180 filmom obloženih tableta EU/1/10/620/006 196 filmom obloženih tableta EU/1/10/620/007 50 x 1 filmom obložena tableta EU/1/10/620/008 196 (2 x 98) filmom obloženih tableta EU/1/10/620/017 168 (2 x 84) filmom obloženih tableta
The reduction in HbA1c for patients treated with sitagliptin, metformin, and insulin was -1.35 % compared to -0.90 % for patients treated with placebo, metformin, and insulin, a difference of -0.45 % [95 % CI: -0.62, -0.29]. 
Sniženje vrijednosti HbA1c u bolesnika liječenih sitagliptinom, metforminom i inzulinom iznosilo je -1,35% u usporedbi s -0,90% u bolesnika koji su liječeni placebom, metforminom i inzulinom, što predstavlja razliku od -0,45% [95 % CI: -0,62; -0,29].
Marketing Authorisation Holder Merck Sharp & Dohme B.V. Waarderweg 39 
Nositelj odobrenja za stavljanje gotovog lijeka u promet Merck Sharp & Dohme B.V.
Reporting of side effects 
NAVOĐENJE DJELATNIH TVARI
Some patients have experienced the following side effects while taking this medicine with a sulphonylurea such as glimepiride: 
Pri istodobnom uzimanju ovog lijeka sa sulfonilurejom, kao što je glimepirid, neki su bolesnici imali sljedeće nuspojave:
For patients inadequately controlled on maximal tolerated dose of metformin monotherapy For patients not adequately controlled on metformin alone, the usual starting dose should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) plus the dose of metformin already being taken. 
U bolesnika koji nisu odgovarajuće regulirani samo metforminom, uobičajena početna doza mora biti 50 mg sitagliptina dvaput na dan (ukupna dnevna doza 100 mg) plus dosadašnja doza metformina.
No treatment related effects on fertility were observed in male and female rats given sitagliptin prior to and throughout mating. 
Kod mužjaka i ženke štakora kojima je sitagliptin dan prije i tijekom parenja nisu zamijećeni učinci na plodnost povezani s primjenom lijeka.
Each film-coated tablet (tablet) contains sitagliptin phosphate monohydrate equivalent to 50 mg of sitagliptin and 850 mg of metformin hydrochloride. 
Jedna filmom obložena tableta (tableta) sadrži sitagliptinfosfat hidrat u količini od 50 mg sitagliptina i 850 mg metforminklorida.
Each film-coated tablet (tablet) contains sitagliptin phosphate monohydrate equivalent to 50 mg of sitagliptin and 1,000 mg of metformin hydrochloride. 
Jedna filmom obložena tableta (tableta) sadrži sitagliptinfosfat hidrat u količini od 50 mg sitagliptina i 1000 mg metforminklorida.
- The active substances are sitagliptin and metformin. 
- Djelatne tvari su sitagliptin i metformin.
Age did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis of Phase I and Phase II data. 
Prema analizi podataka populacijske farmakokinetike faze I i II, dob nije imala klinički značajan utjecaj na farmakokinetiku sitagliptina.
Initial Therapy (twice daily) 
Nakon peroralne primjene doze [
Magyarország MSD Pharma Hungary Kft. Tel.: +36 1 888 53 00 hungary_msd@merck.com 
Tel.: +36 1 888 53 00 hungary_msd@merck.com
Each tablet contains sitagliptin phosphate monohydrate equivalent to 50 mg of sitagliptin and 850 mg of metformin hydrochloride. 
Jedna tableta sadrži sitagliptinfosfat hidrat u količini od 50 mg sitagliptina i 850 mg metforminklorida.
Ristfor 50 mg/1,000 mg tablets sitagliptin/metformin HCl 
Ristfor 50 mg/1000 mg tablete sitagliptin/metforminklorid
Sitagliptin 100 mg once daily added to ongoing pioglitazone + metformin therapy (N=152) 
sitagliptin 100 mg jedanput na dan dodan dotadašnjoj terapiji metforminom (n=453) sitagliptin 100 mg jedanput na dan dodan dotadašnjoj terapiji kombinacijom glimepirid + metformin (n=115) sitagliptin 100 mg jedanput na dan dodan dotadašnjoj terapiji kombinacijom pioglitazon + metformin (n=152) sitagliptin 100 mg jedanput na dan dodan dotadašnjoj terapiji kombinacijom inzulin + metformin (n=223)
Each tablet contains sitagliptin phosphate monohydrate equivalent to 50 mg of sitagliptin and 1,000 mg of metformin hydrochloride. 
Jedna tableta sadrži sitagliptinfosfat hidrat u količini od 50 mg sitagliptina i 1000 mg metforminklorida.
Ristfor 50 mg/850 mg film-coated tablets sitagliptin/metformin hydrochloride 
Ristfor 50 mg/850 mg filmom obložene tablete sitagliptin/metforminklorid
Ristfor 50 mg/850 mg tablets sitagliptin/metformin HCl 
Ristfor 50 mg/850 mg tablete sitagliptin/metforminklorid
Ristfor 50 mg/1,000 mg film-coated tablets sitagliptin/metformin hydrochloride 
Ristfor 50 mg/1000 mg filmom obložene tablete sitagliptin/metforminklorid
For patients inadequately controlled on dual combination therapy with insulin and the maximal tolerated dose of metformin 
Za bolesnike u kojih glikemija nije odgovarajuće regulirana monoterapijom najvišom podnošljivom dozom metformina
Some patients have experienced diarrhoea, nausea, flatulence, constipation, stomach ache or vomiting when starting the combination of sitagliptin and metformin together (frequency is common). 
Pri istodobnom uzimanju kombinacije sitagliptina i metformina neki su bolesnici na početku liječenja imali proljev, mučninu, vjetrove, zatvor, bol u trbuhu ili su povraćali (učestalost je česta).
Mean change from baseline HbA1c (%) 
Srednja vrijednost promjene u odnosu na početni HbA1c
Primary Composite Endpoint (Cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina) 
Primarna objedinjena mjera ishoda (smrt zbog kardiovaskularnog uzroka, infarkt miokarda bez smrtnog ishoda, moždani udar bez smrtnog ishoda ili hospitalizacija zbog nestabilne angine) Sekundarna objedinjena mjera ishoda (smrt zbog kardiovaskularnog uzroka, infarkt miokarda bez smrtnog ishoda ili moždani udar bez smrtnog ishoda)
Cardiovascular death 
(medularnog karcinoma štitnjače)
Some patients have experienced the following side effects while taking this medicine in combination with pioglitazone: 
U nekih bolesnika koji su uzimali metformin nakon dodavanja sitagliptina javile su se sljedeće nuspojave:
Some patients have experienced the following side effects during clinical studies while taking sitagliptin alone (one of the medicines in Ristfor) or during post-approval use of Ristfor or sitagliptin alone or with other diabetes medicines: 
Neki bolesnici koji su u kliničkim ispitivanjima uzimali samo sitagliptin (jednu od djelatnih tvari lijeka Ristfor), kao i bolesnici koji su koristili Ristfor ili sitagliptin, nakon njihova stavljanja u promet, same ili s drugim lijekovima za šećernu bolest, imali su sljedeće nuspojave: Često: nizak šećer u krvi, glavobolja, infekcija gornjih dišnih puteva, začepljen nos ili curenje iz nosa i grlobolja, osteoartritis, bolovi u rukama ili nogama Manje često: omaglica, zatvor, svrbež
Tel: + 386 1 5204201 msd_slovenia@merck.com 
+370 5 278 02 47 msd_lietuva@merck.com
In a pre-/post-natal development study performed in rats sitagliptin showed no adverse effects. 
Sitagliptin nije pokazao štetne učinke u istraživanju prenatalnog i postnatalnog razvoja provedenom na štakorima.
UAB “Merck Sharp & Dohme” Tel. +370 5 278 02 47 msd_lietuva@merck.com 
Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: + 386 1 5204201 msd_slovenia@merck.com
Renal and urinary disorders impaired renal function 
Poremećaji bubrega i mokraćnog sustava poremećaj funkcije bubrega nepoznata učestalost akutno zatajenje bubrega nepoznata učestalost
- if you have type 1 diabetes. 
(pogledajte dio 4.). - ako imate šećernu bolest tipa 1 koja se ponekad naziva šećernom bolešću ovisnom o inzulinu.
Hospitalization for heart failure 
Oštećenje funkcije bubrega
This is sometimes called insulin-dependent diabetes - if you have or have had an allergic reaction to sitagliptin, metformin, or Ristfor (see section 4) - if you are taking a sulphonylurea or insulin, diabetes medicines, together with Ristfor, as you may experience low blood sugar levels (hypoglycaemia). 
- ako imate ili ste imali alergijsku reakciju na sitagliptin, metformin ili Ristfor (pogledajte dio 4.).
tmax is between 3 and 8 hours. 
Vrijednost Tmax je između 3 i 8 sati.
Your doctor will advise you. 
Liječnik će Vas savjetovati.
Children and adolescents 
Djeca i adolescent
- Do not take a double dose to make up for a forgotten dose. 
Nemojte uzeti dvostruku dozu kako biste nadoknadili zaboravljenu dozu.
The volume of distribution is around 10 l/kg. 
Volumen distribucije je oko 10 l/kg.
When opened, use within 3 months. 
Kada se otvori, upotrijebiti unutar 3 mjeseca.
Week 1, 2, 3, 4 Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 
Tjedan 1, 2, 3, 4 Dan 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
To benefit from your medicine you should take it regularly every day at the same time of the day. 
Kako bi imali korist od ovog lijeka, trebate ga uzimati redovito svaki dan, u isto doba dana.
Due to the pharmacological effects and the mechanism of action of memantine the following interactions may occur: 
Zbog farmakoloških učinaka i mehanizma djelovanja memantina moguće su sljedeće interakcije:
Patients with rare hereditary problems of fructose intolerance should not take this medicine. 
Bolesnici s rijetkim nasljednim poremećajem netolerancije fruktoze ne bi trebali uzimati ovaj lijek.
The tablet can be divided into equal doses. 
Tableta se može razdijeliti na jednake doze.
The clinical relevance of these findings is unknown. 
Klinički značaj tih nalaza nije poznat.
Take one tablet once a day. 
Uzmite jednu tabletu jednom dnevno.
Some factors that may raise urine pH (see section 5.2 “Elimination”) may necessitate careful monitoring of the patient. 
Neki čimbenici koji mogu povisiti pH mokraće (vidjeti dio 5.2 “Eliminacija”) mogu zahtijevati pažljivo nadziranje bolesnika.
The effects of barbiturates and neuroleptics may be reduced. 
Učinci barbiturata i neuroleptika mogu biti smanjeni.
There is a possible relationship between this accumulation and the vacuolisation observed in lungs. 
Moguća je povezanost između tog nakupljanja i vakuolizacije opažene u plućima.
Memory loss in Alzheimer's disease is due to a disturbance of message signals in the brain. 
Gubitak pamćenja u Alzheimerovoj bolesti pripisuje se poremećaju prijenosa signala u mozgu.
2 Isolated cases reported in post-marketing experience. 
2 Izolirani slučajevi prijavljeni u postmarketinškom iskustvu.
About 45% of memantine is bound to plasma-proteins. 
Oko 45% memantina veže se na proteine plazme.
In the prospectively defined primary analysis statistical significance was not reached at the primary efficacy endpoint at week 24. 
U prospektivno definiranoj primarnoj analizi nije postignuta statistička značajnost primarnih ishoda djelotvornosti u 24. tjednu.
The treatment scheme is also indicated on the treatment initiation pack. 
Shema liječenja je također opisana u pakovanju za uvođenje liječenja.
Purified water 
voda, pročišćena
Moderate to severe Alzheimer's disease usually causes impairment of driving performance and compromises the ability to use machinery. 
Umjerena do teška Alzheimerova bolest obično uzrokuje oštećenje sposobnosti upravljanja vozilima i kompromitira sposobnost rada sa strojevima.
No specific antidote for intoxication or overdose is available. 
Ne postoji specifični antidot za intoksikaciju ili predoziranje.
Your doctor will tell you whether your illness allows you to drive and to use machines safely. 
Liječnik će Vam reći dopušta li Vam bolest sigurno upravljanje vozilima i rad sa strojevima.
In the event of overdose, treatment should be symptomatic. 
U slučaju predoziranja liječenje treba biti simptomatsko.
Memantine is eliminated in a monoexponential manner with a terminal t½ of 60 to 100 hours. 
Memantin se eliminira monoeksponencijalno s terminalnim t½ od 60 do 100 sati.
The renal elimination rate of memantine under alkaline urine conditions may be reduced by a factor of 7 to 9 (see section 4.4). 
Brzina bubrežne eliminacije memantina u uvjetima alkalnog urina može biti smanjena za faktor od 7 do 9 (vidjeti dio 4.4).
- If you find you have forgotten to take your dose of Memantine Merz, wait and take your next dose at the usual time. 
Ako ustanovite da ste zaboravili uzeti dozu Memantine Merza, pričekajte i uzmite sljedeću dozu u uobičajeno vrijeme.
Instruction for proper use of the pump 
Upute za ispravnu uporabu pumpice
When used for the first time, the dosing pump does not dispense the correct amount of oral solution. 
Kada se koristi prvi put, pumpica za doziranje ne raspršuje ispravnu količinu oralne otopine.
There is one published case report on a possible risk also for the combination of memantine and phenytoin. 
Objavljen je jedan slučaj o mogućem riziku za kombinaciju memantina i fenitoina.
It modulates the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction. 
On modulira učinke patološki povišenih toničkih razina glutamata koje mogu dovesti do disfunkcije neurona.
The tablets should be swallowed with some water. 
Tablete treba progutati s malo vode.
Memantine Merz with food and drink 
Memantine Merz s hranom i, pićem
Always take Memantine Merz exactly as your doctor has told you. 
Uvijek uzimajte Memantine Merz točno onako kako Vam je rekao Vaš liječnik.
If the pump does not function as described during intended use and according to instruction, the patient should consult the treating physician or a pharmacist. 
Ako pumpica ne radi kako je opisano tijekom namijenjene uporabe i prema uputama, bolesnik se treba obratiti nadležnom liječniku ili ljekarniku.
This effect was only observed at high doses in rodents. 
Taj je učinak primijećen samo pri primjeni visokih doza kod glodavaca.
As a consequence, only limited data are available and patients with these conditions should be closely supervised. 
Posljedično tome, dostupni su samo ograničeni podaci, te bolesnike s navedenim stanjima treba pažljivo nadzirati.
<1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Your doctor should assess your treatment on a regular basis. 
Vaš liječnik treba redovito procjenjivati Vaše liječenje.
• Concomitant use of memantine and amantadine should be avoided, owing to the risk of pharmacotoxic psychosis. 
• Potrebno je izbjegavati istodobnu primjenu memantina i amantadina zbog rizika od farmakotoksične psihoze.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder. 
Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje gotovog lijeka u promet.
The same may be true for ketamine and dextromethorphan (see also section 4.4). 
Isto bi moglo vrijediti za ketamin i dekstrometorfan (vidjeti također dio 4.4).
Pharmacotherapeutic group: Other Anti-dementia drugs, ATC code: N06DX01. 
Farmakoterapijska skupina: ostali lijekovi protiv demencije, ATK oznaka: N06DX01.
This effect is known from other active substances with cationic amphiphilic properties. 
Taj je učinak poznat i kod drugih djelatnih tvari s kationskim amfifilnim svojstvima.
The tolerance and dosing of memantine should be reassessed on a regular basis, preferably within three months after start of treatment. 
Podnošljivost i doziranje memantina treba redovito ponovno procjenjivati, po mogućnosti unutar tri mjeseca od početka liječenja.
Memantine has an absolute bioavailability of approximately 100%. 
Apsorpcija Memantin ima apsolutnu bioraspoloživost od približno 100%.
The dosing pump should be locked after use. 
Pumpicu za doziranje treba zaključati nakon uporabe.
Once opened, the contents of the bottle should be used within 3 months. 
Jednom kad se otvori, sadržaj boce treba upotrijebiti unutar 3 mjeseca.
None of these metabolites exhibit NMDA-antagonistic activity. 
Nijedan od navedenih metabolita ne pokazuje NMDA-antagonističku aktivnost.
It is not known whether memantine is excreted in human breast milk but, taking into consideration the lipophilicity of the substance, this probably occurs. 
Nije poznato izlučuje li se memantin u majčino mlijeko ljudi, no, uzimajući u obzir lipofilnost tvari, do toga vjerojatno dolazi.
Once daily 
Jedanput dnevno
There is increasing evidence that malfunctioning of glutamatergic neurotransmission, in particular at NMDA-receptors, contributes to both expression of symptoms and disease progression in neurodegenerative dementia. 
Sve je više dokaza da slabo funkcioniranje glutamatergične neurotransmisije, posebice na NMDA-receptorima, doprinosi izraženosti simptoma i progresiji bolesti kod neurodegenerativne demencije.
Memantine should not be used during pregnancy unless clearly necessary. 
Memantin se ne smije primjenjivati tijekom trudnoće, osim ako to nije izričito potrebno.
1 Hallucinations have mainly been observed in patients with severe Alzheimer´s disease. 
1 Halucinacije su opažene uglavnom kod bolesnika s teškom Alzheimerovom bolešću.
Both compounds are chemically related NMDA-antagonists. 
Oba spoja su kemijski srodni NMDA-antagonisti.
Psychotic reactions2 
Nepoznato psihotične reakcije2
As the effects have neither been observed in long term studies in rodents nor in non-rodents, the clinical relevance of these findings is unknown. 
Budući da učinci nisu bili primijećeni u dugoročnim ispitivanjima na glodavcima i neglodavcima, klinički značaj ovih nalaza nije poznat.
For detailed instructions on the preparation and handling of the product see end of this leaflet. 
Za detaljne upute o pripremi i postupanju s lijekom, vidjeti kraj ove upute.
In particular, Memantine Merz may change the effects of the following medicines and their dose may need to be adjusted by your doctor: 
Posebice, Memantine Merz može promijeniti učinak sljedećih lijekova, te će liječnik možda morati prilagoditi njihovu dozu:
Therapy should only be started if a caregiver is available who will regularly monitor the intake of the medicinal product by the patient. 
Terapiju treba započeti samo ako je dostupan njegovatelj koji će redovito nadzirati bolesnikovo uzimanje lijeka.
This dose will be increased weekly by 5 mg until the recommended (maintenance) dose is reached. 
Ova doza će se povećavati za 5 mg tjedno dok se ne postigne preporučena doza (doza održavanja).
In short term studies in rats memantine like other NMDA-antagonists have induced neuronal vacuolisation and necrosis (Olney lesions) only after doses leading to very high peak serum concentrations. 
U kratkoročnim ispitivanjima na štakorima, memantin je, kao i drugi NMDA-antagonisti, uzrokovao neuronsku vakuolizaciju i nekrozu (Olney lezije) samo nakon doza koje su dovodile do vrlo visokih vršnih serumskih koncentracija.
If tolerated well after at least 7 days of treatment, the dose could be increased up to 20 mg/day according to standard titration scheme. 
Ako se lijek dobro podnosi tijekom razdoblja liječenja od najmanje 7 dana, doza se može povećati do 20 mg/dan prema standardnoj shemi titriranja.
Diagnosis should be made according to current guidelines. 
Dijagnozu treba postaviti prema važećim smjernicama.
Week 2 (day 8-14): 
2. tjedan (8. - 14. dan):
Date of first authorisation: 22 Nov 2012 Date of latest renewal: {DD month YYYY} 
Datum prvog odobrenja: 22 studeni 2012.